CatalYm GmbH

The FDA approved three immunotherapy drugs for resectable NSCLC without clear evidence on their benefits before or after surgery. Oncologists face dilemmas in treatment decisions due to lack of data on when immunotherapy is most effective. Recent discussions suggest neoadjuvant therapy may offer more benefits than adjuvant, potentially reducing unnecessary treatments and risks.

European health tech investment rebounded in Q3 2024, with healthtech securing more VC than any other sector, driven by AI and oncology startups. Despite a 35% decline in overall startup funding, total European tech investment in 2024 is on track to match 2023's $58.2bn, fueled by AI-powered healthtech and generative AI. Oncology startups raised nearly $600m, with Catalym and Myricx Bio securing $150m and $117m respectively. The UK led in funding with $2.9bn, followed by Germany and France.

Multiple biotech companies raise significant funding for various drug development and clinical trial initiatives, including Cardurion Pharmaceuticals ($260M for cardiovascular therapies), Formation Bio ($372M for AI drug discovery), Element Biosciences ($277M for DNA sequencing), and others targeting cancer, neurodegenerative diseases, and more.